Skip to main content
NCBI home page
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2000 Nov 23;10(6):395–403. doi: 10.1002/1099-1654(200011/12)10:6<395::AID-RMV298>3.0.CO;2-V

Innate defences against viraemia

Indra P Singh 1, Samuel Baron 1,✉
PMCID: PMC7159352  PMID: 11114078

Abstract

Human blood plasma has been reported to possess nonspecific antiviral activity. This activity is due to several preexisting naturally occurring molecules that are either active against individual members or a family of viruses. These molecules, however, have not been adequately studied to reveal their molecular structures and mechanisms of action presumably because of their low and nonspecific antiviral action. Therefore, their possible role against viraemia remains unknown. Recently, two naturally occurring nonspecific broad‐spectrum antiviral agents, University of Texas Inhibitor β (UTIβ) glycoprotein and high density lipoprotein, have been described in human serum. They are active against DNA and RNA viruses and one of them, UTIβ, possesses significant antiviral activity of 40 units/mL. Since preexisting antiviral molecules in serum appear to be the only defence mechanisms available at the onset of viral infection they may have protective significance against viraemia. In view of this potential, we have undertaken to review the properties of these innate viral inhibitory molecules. Copyright © 2000 John Wiley & Sons, Ltd.

REFERENCES

  • 1. Smorodintsev AA. Basic mechanism of nonspecific resistance to viruses in animals and man. Adv Virus Res 1960; 7: 327–376. [Google Scholar]
  • 2. Ginsberg HS. Serum and tissue inhibitors of virus. Bacteriol Rev 1960; 24: 141–150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Singh IP, Coppenhaver DH, Chopra AK, Baron S. Further characterization of a broad‐spectrum antiviral substance in human serum. Immunology 1992; 5: 293–303. [DOI] [PubMed] [Google Scholar]
  • 4. Singh IP, Chopra AK, Coppenhaver DH, Ananthramiah GM, Baron S. Lipoproteins account for part of the broad non‐specific antiviral activity of human serum. Antiviral Res 1999; 42: 211–218. [DOI] [PubMed] [Google Scholar]
  • 5. Gerna G, Cattaneo E, Cereda PM, Revelo MG, Achilli G. Human coronavirus OC43 serum inhibitor and neutralizing antibody by a new plaque‐reduction assay. Proc Soc Exp Biol Med 1980; 163: 360–366. [DOI] [PubMed] [Google Scholar]
  • 6. Karzon DT. Non‐specific viral inactivating substance (VIS) in human and mammalian sera. J Immunol 1956; 76: 454–463. [PubMed] [Google Scholar]
  • 7. Kitamura T, Tanaka Y, Sugane M. Studies on a heat‐labile variola virus inhibitor in normal serum. II. Further characterization of the inhibitor and its activity. Intervirology 1973; 1: 288–296. [DOI] [PubMed] [Google Scholar]
  • 8. Suribaldi L, DeStasio A, Mastromarino P, Seganti L, Valenti I, Orsi N. Different sensitivity of hemagglutinating and hemolytic activities of Sendai virus to non‐antibody inhibitors. Boll 1st Sieroter Milan 1979; 58 (5): 365–370. [PubMed] [Google Scholar]
  • 9. Thiry L, Cogniaux‐Le Clerk J, Content J, Tack L. Factors which influence inactivation of vesicular stomatitis virus by fresh human serum. Virology 1978; 74: 432–440. [DOI] [PubMed] [Google Scholar]
  • 10. Kriznova O, Rathova V. Serum inhibitors of myxoviruses. Curr Top Microbiol Immunol 1969; 47: 125–151. [DOI] [PubMed] [Google Scholar]
  • 11. Shortridge KF, Ho WKK. Human serum lipoproteins as inhibitors of haemagglutination for selected togaviruses. J Gen Virol 1974; 33: 523–527. [DOI] [PubMed] [Google Scholar]
  • 12. Welsh RM Jr, Jensen FC, Cooper NR, Oldstone MA. Inactivation and lysis of ocornaviruses by human serum. Virology 1976; 74: 432–440. [DOI] [PubMed] [Google Scholar]
  • 13. Baba M, Pauwels R, Balzarini J, Arnout J, Desmyter J, De Clerq E. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro . Proc Soc Acad Sci USA 1988; 85: 6132–6136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Rider CC. The potential for heparin and its derivatives in the therapy and prevention of HIV‐1 infection. Glycoconj J 1997; 14: 639–642. [DOI] [PubMed] [Google Scholar]
  • 15. Nahmias AJ, Kibrick S. Inhibitory effect of heparin on herpes simplex virus. J Bacteriol 1964; 87: 1060–1066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Baron S, Dianzani F, Stanton GJ, Fleischmann WR., Jr (eds). The Interferon System: A Current Review to 1987. University of Texas Press, Austin, 1987. [Google Scholar]
  • 17. Sambhi SK, Kohonen‐Corish MR, Ramshaw IA. Local production of tumor necrosis factory encoded by recombinant vaccinia virus is effective in controlling virus replication in vivo . Proc Natl Acad Sci USA 1991; 88: 4025–4029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Czarniecki CW. The role of tumor necrosis factor in viral disease. Antiviral Res 1993; 22: 223–258. [DOI] [PubMed] [Google Scholar]
  • 19. Wallace MR, Woelfl I, Bowler WA, et al Tumor necrosis factor, interleukin‐2, and interferon‐gamma in adult varicella. J Med Virol 1994; 43: 69–71. [DOI] [PubMed] [Google Scholar]
  • 20. Baron S, Neisel D, Singh IP, et al Recently described innate broad‐spectrum virus inhibitors. Microb Pathol 1989; 7: 237–247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Baron S, McKerlie L. Broadly active inhibitor if viruses spontaneously produced by many cell types in culture. Infect Immun 1981; 32: 449–453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Owens BL, Ananthramaiah GM, Kahlon JB, Srinivas RV, Compans RW, Segrest JP. Apolipoprotein A‐1 and its amphipathic helix peptide analogues inhibit human immunodeficiency virus‐induced syncitium formation. J Clin Invest 1990; 4: 1142–1150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Srinivas RV, Birkedal B, Owens RJ, Anantharamaiah GM, Segrest JP, Compans RW. Antiviral effects of lipoprotein A‐1 and its synthetic amphipathic peptide analogs. Virology 1990; 176: 48–57. [DOI] [PubMed] [Google Scholar]
  • 24. Singh IP, Chopra AK, Coppenhaver DH, Smith E, Poast J, Baron S. Vertebrate brains contain a broadly active antiviral substance. Antiviral Res 1995; 27: 375–388. [DOI] [PubMed] [Google Scholar]
  • 25. Baron S, Chopra AK, Coppenhaver DH, Gelman BB, Poast J, Singh IP. A defense role for a natural antiviral substance in the nervous system. J Neuroimmunol 1998; 85: 168–175. [DOI] [PubMed] [Google Scholar]
  • 26. Bang FB, Foard M, Karzon DT. The determination and significance of substances neutralizing Newcastle disease virus in human serum. Johns Hopkins Hosp Bull 1950; 87: 130–143. [PubMed] [Google Scholar]
  • 27. Sawicki L, Rykoweska R. The guinea pig and white rat serum inhibitors as a possible factor of natural resistance of these animals to infection with certain strains of influenza virus. Med Dosw Mikrobiol 1963; 12: 55–64.[In Polish]. [PubMed] [Google Scholar]
  • 28. Smorodintsev AA. Factors of natural resistance and specific immunity to viruses. Virology 1957; 3: 299–321. [DOI] [PubMed] [Google Scholar]
  • 29. Borecky L, Kociskova D, Hana L. An attempt to affect the level of serum inhibitors of myxoviruses in vivo. I. Effect of ethionine administration on the level of inhibitors in guinea‐pig sera. Acta Virol 1961; 5: 236–2444. [Google Scholar]
  • 30. Borecky L, RathovaV, Kociskova D. An attempt to affect the level of inhibitors of myxoviruses in vivo. II. Effect of ethionine administration on virus multiplication. Acta Virol 1962; 6: 97–104. [Google Scholar]
  • 31. Borecky L, Rathova V, Kociskova D, Hana L. Effect of d‐l ethionine on some factors of nonspecific resistance to myxoviruses. J Hyg Epidem (Praha) 1962; 6: 65–70. [PubMed] [Google Scholar]
  • 32. Davoli R, Bartolomei‐Corsi O. Nonspecific inhibition of haemagglutination by influenza viruses. VI. Haemmaglutination‐inhibition and neutralization of infectivity. If influenza viruses of type A2 by normal guinea‐pig serum activated by heat. Sperimentale 1959; 109: 32–42. [Google Scholar]
  • 33. Cohen A. Protection of mice against Asian influenza virus infection by a normal horse serum inhibitor. Lancet 1960; 11: 791–794. [DOI] [PubMed] [Google Scholar]
  • 34. Casazza AM, Di Marco A, Ghione M, Zanella A. Biological properties of horse serum inhibitor against influenza A2 viruses. G Microbiol 1964; 12: 1–14. [Google Scholar]
  • 35. Link F, Blaskovic D, Raus J. On the therapeutic effect of gamma inhibitor in mice infected with an inhibitor‐sensitive unadapted A2 influenza virus. Acta Virol 1965; 9: 553. [PubMed] [Google Scholar]
  • 36. Link F, Szanto J, Kriznova O. A quantitative assay of the in vivo protective effect of gamma inhibitor against inhibitor sensitive A2 influenza virus. Acta Virol 1964; 8: 71–75. [PubMed] [Google Scholar]

Articles from Reviews in Medical Virology are provided here courtesy of Wiley

RESOURCES